

# TECNIS Eyhance™ IOL

Backed by both quality and quantity

TECNIS Eyhance™ has high-quality evidence evaluating intermediate performance.

Studies reporting intermediate-specific PROs† further verify benefit for patients implanted with TECNIS Eyhance™ IOL.

Studies showed **80%** of TECNIS Eyhance™ patients reported not using spectacles for intermediate tasks

**Note:** Studies with intermediate vision as endpoints: 48 for TECNIS Eyhance™; 8 for IsoPure; 2 for RayOne EMV® and 1 for ZOE®; exclude 2 Eyhance™ & 1 IsoPure studies show comparable intermediate vision to conventional monofocal

\*Search date: 4 Nov 2024. Search platform: PubMed, EMBASE


**Johnson & Johnson**

## #1 most studied IOL for intermediate performance



Proportional level of evidence for each enhanced monofocal, regardless of comparators.\*

Figure 1: Hierarchy of evidence\*



† Preliminary results of nonrandomized, prospective, clinical study evaluating visual outcome, optical quality, patient satisfaction and intermediate vision in bilaterally implanted cataract patients (n=40) at 1-day, 1-week, 1 month and 6 months post-operative.

‡ Prospective, bilateral, randomized, comparative/evaluator-masked, controlled study (n=139 patients) evaluating monocular and binocular visual acuity, patient reported outcomes and safety.

Third party trademarks are the property of their respective owners.

© Johnson & Johnson and its affiliates 2025  
2025PP09810 v3

## Evidence Level a

1. Wan KH, Au ACK, Kua WN, Ng ALK, Cheng GPM, Lam NM, Chow VWS. Enhanced Monofocal Versus Conventional Monofocal Intraocular Lens in Cataract Surgery: A Meta-analysis. *J Refract Surg.* 2022;38(8):538-546.2.

2. Redruello-Guerrero P, Rivera-Izquierdo M, Jiménez-Gutiérrez Z, Láinez-Ramos-Bossini AJ, Yela R, López-Marín L. Improvement of intermediate vision with new monofocal intraocular lenses: A systematic review and meta-analysis. *Eur J Ophthalmol.* 2023; 33(3):1308-1319

3. Fernández J, Rocha-de-Lossada C, Zamorano-Martín F, Rodríguez-Galvo-de-Mora M, Rodríguez-Vallejo M. BMC Ophthalmol. 2023. 23(1):101.

## Evidence Level lb

4. Auffarth GU, Gerl M, Tsaï L, Dragotta M, Jackson B, Alarcon A, Dick HB; Quantum Study Group. Clinical evaluation of a new monofocal IOL with enhanced intermediate function in patients with cataract. *J Cataract Refract Surg.* 2021. 47(2):184-191.

5. Nanavaty MA, Ashena Z, Gallagher S, Borkum S, Frattaroli P, Barbon E. *J Refract Surg.* 2022. 38(1):10-20.

6. Choi WK, Han HJ, Son HS, Khoramnia R, Auffarth GU, Choi CY. BMC Ophthalmol. 2023. 23(1):157.

7. Donoso R, Torres A, Klages J, Mercado Y, Gonzalez T, Astudillo M, Norambuena H, Medina E. *J Cataract Refract Surg.* 2023. 49(8):818-825.

8. Goslings O, Verhaar H, van de Laar-Musken J, Piñero DP. Graefes Arch Clin Exp Ophthalmol. 2023. 261(8):2315-2326

9. Sandoval HP, Poltvin R, Solomon KD. Clin Ophthalmol. 2023; 17:3693-3702.

10. Hida WT, Moscovici BK, Cortez CM, Colombo-Barboza GN, Izelkiss PFM, Motta AFP, De Medeiros AL, Nose W, Garricondo PC. *J Cataract Refract Surg.* 2024. 50(4):401-406

11. Giglio R, Vinciguerra AL, Presotto M, Jonak K, Rejdak R, Toro MD, Nanavaty MA, Tognetto D. *Int Ophthalmol.* 2024. 44(1):112

12. Corbett D, Black D, Roberts TV, Cronin B, Gunn D, Bala C, Versace P, Tsai L, Papadoulou E, Alarcon A, Vilupuru S. *Eye (Lond).* 2024. 38(1):9-14

13. Black DA, Bala C, Alarcon A, Vilupuru S. *Eye (Lond).* 2024;38(1):15-20

14. Zeilinger J, Kronschlager M, Schlatter A, Georgiev S, Ruiss M, Pilwachs C, Findl O. *Am J Ophthalmol.* 2024 Oct 25;S0002-9394(24)00482-3.

## Evidence Level ll

15. de Luis Equileor B, Martínez-Indart L, Martínez Alch N, Saoristán Eguén C, Cuadros Sánchez de Arad Soc Exp Oftalmol. 2020;95(1):523-527

16. Steinmüller LN, Greve D, Rua Amaro D, Bertelmann E, von Sonntagleitner C. *Eur J Ophthalmol.* 2023; 6(1):2096-2105

17. Salgado-Borges J, Borges A, Ferreira I, González-Mejmeim JM, Faria-Ribeiro M. *Graefes Arch Clin Exp Ophthalmol.* 2024. 262(5):1559-1544

18. Danzinger V, Schartmüller D, Lisy M, Schranz M, Schwarzenbacher L, Abela-Formanek C, Menapace R, Leydolt C. *Am J Ophthalmol.* 2024. 261:95-102

19. Sihmar Y, Singh BK, Singh VK, Kumar S, Chaudhary A, Saini S, Saudi J. *Ophthalmol.* 2023 Dec 1;37(4):331-336

20. Singh G, Sidharthan KS, Reddy JK, Sundaram V, Thulassani M. *Indian J Ophthalmol.* 2024. 72(2):181-184

21. Suzuki H, Nishiyama M. *Clin Ophthalmol.* 2024. 18:671-678.

22. Choi SH, Choi IH, Jeon GS, Chang IB, Ma DJ, Hong IH. *Ophthalmic Res.* 2024. 67(1):221-231.

23. Jukić T, Bajraktari G, Vukojecić N, Oroz M, Radolović A, Mandić K, Kalauz M. *Ophthalmologica.* 2024 Jul 30:1-10

24. Choi SH, Lee HS, Chang IB, Ma DJ, Choi IH, Lee SJ, Hong IH. *Curr Eye Res.* 2023 Oct;48(10):904-910.

25. Black DA, Bala C, Alarcon A, Vilupuru S. *Eye (Lond).* 2023 Dec 18;16(12):2004-2010.

26. Rocha KM, Costa ED, Dodhia M, Waring GO 4th S, Ruiss M. *Pilwachs C, Findl O. Am J Ophthalmol.* 2024 Oct 25;S0002-9394(24)00482-3.

27. Giansanti F, Dragotto F, Nicolosi C, Alonzo L, Ciferri L, Franco FS, Vannozzi I, Abruzzese G, Bacherini D, Virgili G. *J Clin Med.* 2023 Jul 30;12(15):5016

28. Park MJ, Lee HS, Chang IB, Hong IH. *Korean J Ophthalmol.* 2023 Oct;37(5):401-408

29. Nam JW, Lee JH, Zhang H, Sung MS, Park SW. *J Clin Med.* 2023 Sep 7;12(18):5830

30. Shetty N, Shetty R, Ranade R, Narasimhan R, Artal P, Nujitsi RMA, Sinha Roy AJ. *Cataract Refract Surg.* 2024 Jan 1;50(1):30-36.

## Evidence Level III

31. Unsai U, Sabur H. *Int Ophthalmol.* 2021 Jan;41(2):273-282

32. Kang KH, Song MY, Kim KY, Hwang KY, Kwon YA, Koh K. *Korean J Ophthalmol.* 2021. 35(2):112-119.

33. Huh J, Eom Y, Yang SK, Choi Y, Kim HM, Song JS. *BMC Ophthalmol.* 2021. 21(1):365

34. Lopes D, Loureiro T, Carneira R, Rodrigues Barros S, Cardoso JN, Campos P, Machado I, Campos N. *Eur J Ophthalmol.* 2022. 52(1):229-234

35. Jeon YJ, Yoon Y, Kim TI, Koh K. *Asia Pac J Ophthalmol (Phila).* 2021 Oct 1;10(6):542-547.

36. Karupiah P, Varman NVA, Varman A, Balakumar D. *Indian J Ophthalmol.* 2022 Aug;70(8):2867-2871.

37. Sabur H, Unsai U. *Eur J Ophthalmol.* 2023 Jan;33(1):262-268.

38. Micheletti JM, Duncan NB, Hall B. *Clin Ophthalmol.* 2023 Dec 21;17:3983-3990.

39. Sugawara K, Ito R, Horiguchi H, Mizobuchi K, Katagiri S, Gunji H, Nakano T. *Int J Ophthalmol.* 2023 Dec 18;16(12):2004-2010.

40. Mennucci R, Romualdi G, De Vitto C, Cennamo M. *Life (Base).* 2023 Apr;9(12):243

41. Dell SJ, Hannan SJ, Venter JA, Teenan D, Hannan NC, Raju D, Berry CW, Kiss HJ, Schallhorn JM. *Clin Ophthalmol.* 2024 May 1;18:1157-1169

42. Choi JY, Won YK, Lee SJ, Kang SW, Lim DH. *Bioengineering (Base).* 2024 Sep 19;11(9):939

43. Buzzonetti L, Petroni S, Federici M, Valente P, De Sanctis C, Iarossi G. *J Refract Surg.* 2024 Oct;40(10):e724-e727

44. Jeong S, Son S, Sagong M. *Sci Rep.* 2024 Oct 17;14(1):24377

45. Jeon YJ, Lee H, Eah KS, Park N, Chung HS, Kim JY, Tchah H, Lee H. *Eye Vis (Lond).* 2024 Nov 11(1):42

46. Cinar E, Bolu H, Erbakan G, Yuce B, Aslan F, Fece M, Erme S. *Int Ophthalmol.* 2021 Feb;41(2):491-498

47. García-Bella J, Burgos-Blasco B, Vidal-Villegas B, Gabón N, Villanueva C, García-Fernjo J. *J Cataract Refract Surg.* 2024 Jun 15(06):585-590.

48. Can İ, Bayhan HA. *Turk J Ophthalmol.* 2024 Aug

28;54(4):190-197.

49. Kim DR, Yoon YC, Whang WJ, Hwang HS, Na KS. *BMC Ophthalmol.* 2024 Feb 19;24(1):74.

## Evidence Level IV

50. Mennucci R, Cennamo M, Venturi D, Vignapiano R, Favuzza E. *J Cataract Refract Surg.* 2020 Mar;46(3):378-387

51. Lee JH, Moon SY, Chung HS, Park SY, Lee H, Kim JY, Tchah H. *J Cataract Refract Surg.* 2022 Jan 1;48(1):61-66

52. Corbelli E, Iuliano L, Bandello F, Fasce F. Analysis and comparison of monofocal, extended depth of focus and trifocal intraocular lens profiles. *J Cataract Refract Surg.* 2022 Jan 1;48(1):67-74

53. Blancafort A-Mias S, Del Campo Carrazo Z, Salvador-Allarés L, Luna Marín S, Gómez Prieto MJ, Liñán Martín F, Salvá Casanovas A.

54. Fernández-Vega-Cueto L, Vega F, Guerra-Velasco R, Millán MS, Madrid-Gosta D, Alfonso JF. *J Refract Surg.* 2022 Sep;38(9):572-579

55. Park ES, Ahn H, Han SJ, Jun I, Seo KY, Kim EK, Kim TI. *Sci Rep.* 2022 Dec 15;12(1):21716

56. Gigon E, Bouthour W, Panos GD, Pajic B, Massa H. *Eur J Ophthalmol.* 2023 May;33(3):1390-1397

57. Abd Elghaffar Shehata M, Hosny MH, Tolba DA, Athya M. *Clin Ophthalmol.* 2022 Dec 21;16:4257-4261

58. Beltraminelli T, Rizzato A, Toniolo K, Galli A, Menghini M. *BMC Ophthalmol.* 2023 Apr 21;23(1):170

59. Mennucci R, Morelli A, Cennamo M, Roszkowska AM, Favuzza E. *J Clin Med.* 2023 May 21;12(10):3588

60. Corbelli E, Iuliano L, Codonetti M, Fasce F, Bandello F. *J Cataract Refract Surg.* 2023 Sep 1;49(9):929-935

61. Negishi K, Masui S, Ayaki M, Torii H, Yotsukura E, Nishi Y. *Clin Ophthalmol.* 2023 Dec 21;17:3965-3973

62. Odobasic M, Bisevic A, Ahmedbegovic-Pjano M, Skopljak-Salkica A, Pandurevic B. *Acta Inform Med.* 2023;33(4):322-325

63. Hwang HS, Lee H, Park JH, Chae JB, Kim DY. *Int Ophthalmol.* 2024 Feb 20;44(1):104

64. Banerjee S, Kaufmann C, Tinner C, Jselin K, Armstutz CA, Heding YM, Schmid MK, Thiel M. *Klin Monbl Augenheilkd.* 2024 Apr;241(4):369-373

65. Komatsu K, Masuda Y, Tachibana S, Sano K, Iida M, Ichihara K, Oki T, Fukai K, Tatemichi M, Nakano T. *J Refract Surg.* 2024 Jul;40(7):e499-e505

66. Hwang HS, An D, Kim HS, Kim EC. *BMC Ophthalmol.* 2024 Aug 27;24(1):378

67. Łabuz G, Son HS, Naujokaitis I, Yildirim TM, Khoramnia R, Auffarth GU. *Ophthalmol Ther.* 2021 Dec;10(4):1093-1104

68. Danzinger V, Schartmüller D, Schwarzenbacher L, Millán MS, Abela-Formanek C, Menapace R, Leydolt C. *Eye (Lond).* 2024 Feb;38(2):321-327.

## Evidence Level V

69. Tognetto D, Cecchini P, Giglio R, Turco G. *J Cataract Refract Surg.* 2020 Jun;46(6):902-906

70. Vega F, Millán MS, Gil MA, Garzón N. *J Refract Surg.* 2020 Sep 1;36(9):625-632

71. Schmid R, Borkenstein AF, Graefes Arch Clin Exp Ophthalmol. 2022 Dec;260(2):609-620. doi: 10.1007/s00417-021-05362-2. Epub 2021 Aug 9.

72. Ungewiss J, Röck T, Wörner M, Wetzel D, Bartz-Schmidt KU, Schiefer U. *Klin Monbl Augenheilkd.* 2022 Aug;239(8):996-1004

73. Pieh S, Artmayr C, Pai V, Schartmüller D, Kriechbaum F. *J Refract Surg.* 2022 Aug;38(8):497-501

74. Schmid R, Fuchs C, Luedtke H, Borkenstein AF, Eur J Ophthalmol. 2023 Jan;33(1):257-261.68.Schmid

R, Luedtke H, Borkenstein AF. *Eur J Ophthalmol.* 2022 Sep 26.

75. Azor JA, Vega F, Armengol J, Millan MS. *J Refract Surg.* 2022 Nov;38(11):688-697

76. Alarcon A, Canovas C, Koopman B, Pande MV, Koch DD, Piers P. *BMC Ophthalmol.* 2023 Mar 20;23(1):12.

77. Du QX, Liu XM, Ma WH, Huang YS. *Zhonghua Yan Ke Za Zhi.* 2024 Jun 11;60(6):494-502

78. Vega F, Garzón N, García-Montero M, Millán MS. *J Cataract Refract Surg.* 2024 Jul 16.

79. Acr NO. *Indian J Ophthalmol.* 2024 Oct 1;72(10):1530-1531.

80. Micheletti JM, McCauley MB, Duncan N, Hall B. *Clin Ophthalmol.* 2023 Dec 7;17:3739-3746.

81. Miret JJ, Camps VJ, Garcia C, Gabbalero MT, Gonzalez-Leal JM. *Graefes Arch Clin Exp Ophthalmol.* 2024 Sep 17.

82. Ribeiro F, Piñero DP, Dick HB, Findl O, Cochener B, Kohnen T. *J Cataract Refract Surg.* 2024 Aug 15;0(8):789-793.

## INDICATIONS AND IMPORTANT SAFETY INFORMATION FOR TECNIS Eyhance™ and TECNIS Eyhance™ Toric II IOLs with TECNIS SIMPLICITY™ Delivery System

**INDICATIONS FOR USE** The TECNIS SIMPLICITY™ Delivery System is used to fold and assist in inserting the TECNIS Eyhance™ IOL for the visual correction of aphakia in adult patients in whom a cataractous lens has been removed by extracapsular cataract extraction. The lens is intended to be placed in the capsular bag. The TECNIS SIMPLICITY™ Delivery System is used to fold and assist in inserting the TECNIS Eyhance™ Toric II IOLs for the visual correction of aphakia and pre-existing corneal astigmatism of one diopter or greater in adult patients with or without presbyopia in whom a cataractous lens has been removed by phacemulsification and who desire reduction in residual refractive cylinder. The lens is intended to be placed in the capsular bag.

**WARNINGS** Physicians considering lens implantation under any of the following circumstances should weigh the potential risk/benefit ratio:

1. Patients with any of the following conditions may not be suitable candidates for an intraocular lens because the lens may exacerbate an existing condition, may interfere with diagnosis or treatment of a condition or may pose an unreasonable risk to the patient's eyesight. These conditions are not specific to the design of the lens and are attributed to cataract surgery and IOL implantation in general:
  - a. Patients with recurrent severe anterior or posterior segment inflammation or uveitis of unknown etiology, or any disease producing an inflammatory reaction in the eye.
  - b. Patients in whom the intraocular lens may affect the ability to observe, diagnose or treat posterior segment diseases.
  - c. Surgical difficulties at the time of cataract extraction, which may increase the potential for complications (e.g., persistent bleeding, significant iris damage, uncontrolled positive pressure or significant vitreous prolapse or loss).
  - d. A compromised eye due to previous trauma or developmental defects in which appropri-

- e. Circumstances that would result in damage to the endothelium during implantation.
- f. Suspected microbial infection.
- g. Patients in whom neither the posterior capsule nor the zonules are intact enough to provide support for the IOL.
- h. Congenital bilateral cataracts.
- i. Previous history of, or a predisposition to, retinal detachment.
- j. Patients with only one good eye with potentially good vision.
- k. Medically uncontrollable glaucoma.
- l. Corneal endothelial dystrophy.
- m. Proliferative diabetic retinopathy.
- n. Children under the age of 2 years are not suitable candidates for intraocular lenses.

2. The lens should be placed entirely in the capsular bag. Do not place the lens in the ciliary sulcus.
3. Johnson & Johnson Surgical Vision, Inc. single-use medical devices are labeled with instructions for use and handling to minimize exposure to conditions which may compromise the product, patient, or the user. When used according to the directions for use, the delivery system minimizes the risk of infection and/or inflammation associated with contamination.
4. The reuse/resterilization/reprocessing of Johnson & Johnson Surgical Vision, Inc. single-use devices may result in physical damage to the medical device, failure of the medical device to perform as intended, and patient illness or injury due to infection, inflammation, and/or illness due to product contamination, transmission of infection, and lack of product sterility.
5. The clinical study for the TECNIS™ Toric 1-Piece IOL did not show evidence of effectiveness for the treatment of preoperative corneal astigmatism of less than one diopter.
6. Rotation of the toric lens from its intended axis can reduce its astigmatic correction. Misalignment greater than 30° may increase postoperative re-

- fractive cylinder. If necessary, lens repositioning should occur as early as possible prior to lens encapsulation.
7. Do not attempt to disassemble, modify or alter the delivery system or any of its components, as this can significantly affect the function and/or structural integrity of the design.
8. Do not use if the cartridge of the delivery system is cracked or split prior to implantation.
9. Do not implant the lens if the rod tip does not advance the lens or if it is jammed in the delivery system.
10. During initial lens advancement, quick advancement of the plunger is needed. Do not stop or reverse while advancing the plunger. Doing so may result in improper folding of the lens.
11. After initial lens advancement and the half turn rotation step, do not move the plunger forward until ready for lens implantation. Doing so may result in the lens being stuck in the cartridge.
12. The lens and delivery system should be discarded if the lens has been folded within the cartridge for more than 10 minutes. Not doing so may result in the lens being stuck in the cartridge.

**PRECAUTIONS** The safety and effectiveness of the TECNIS Eyhance™ IOL and TECNIS Eyhance™ Toric II IOL has not been substantiated in clinical trials. The effects of the TECNIS Eyhance™ IOL optical design on quality of vision, contrast sensitivity, and subjective visual disturbances (glare, halo, etc.) have not been evaluated clinically. MTF testing of the TECNIS Eyhance™ IOL may aid the Surgeon in understanding the theoretical image quality expected with the TECNIS Eyhance™ IOL compared to other Johnson & Johnson Surgical Vision monofocal IOLs (AAB00 and ZCB00). However, these do not fully assess all aspects of clinical difficulties under all conditions. Surgeons must weigh the potential benefits of the modified optical design of the TECNIS Eyhance™ IOL against the potential for risks and the lack of clinical data to characterize the impact of the TECNIS Eyhance™ IOL optical design on contrast

## Rx Only

- sensitivity and subjective visual disturbance. These considerations may be especially relevant to patients with certain pre-existing ocular conditions (prior corneal refractive surgery, irregular corneal astigmatism, severe corneal dystrophy, macular disease, optic nerve atrophy, etc.) or intraoperative conditions (posterior capsular rupture, complications in which the IOL stability could be compromised, inability to place IOL in capsular bag, etc.).
13. Prior to surgery, the surgeon must inform prospective patients of the possible risks and benefits associated with the use of this device and provide a copy of the patient information brochure to the patient.
  14. Some autorefractors utilize only the central part of the IOL to calculate the refraction of the eye and that is the region where the TECNIS Eyhance™ deviates from the monofocal design which could result in a wrong estimation of the refraction. Manual refraction with maximum plus technique is strongly recommended.
  15. Recent contact lens usage may affect the patient's refraction; therefore, for patients who wear contact lenses, surgeons should establish corneal stability without contact lenses prior to determining IOL power.
  16. The lens is designed for optimum visual performance when emmetropia is targeted.
  17. This is a single use device, do not re-sterilize the lens or the delivery system. Most sterilizers are not equipped to sterilize the soft acrylic material and the preloaded inserter material without producing undesirable side effects.
  18. Do not store the device in direct sunlight or at a temperature under 5°C (41°F) or over 35°C (95°F).
  19. Do not autoclave the delivery system.
  20. Do not advance the lens unless ready for lens implantation.
  21. The contents are sterile unless the package is opened or damaged.
  22. The recommended temperature for implanting the lens is at least 17°C (63°F).

23. The use of Balanced Salt Solution or viscoelastics is required when using the delivery system. For optimal performance when using OVD, use the HEALON™ family of viscoelastics. The use of Balanced Salt Solution with additives has not been studied for this product.
24. Do not use if the delivery system has been dropped or if any part was inadvertently struck while outside the shipping box. The sterility of the delivery system and/or the lens may have been compromised.
25. Do not leave the lens in a folded position more than 10 minutes.
26. When the delivery system is used improperly, the lens may not be delivered properly (i.e., haptics may be broken). Please refer to the specific instructions for use provided.
27. Carefully remove all viscoelastic and do not over-inflate the capsular bag at the end of the case. Residual viscoelastic and/or over-inflation of the capsular bag may allow the lens to rotate, causing misalignment of the TECNIS Eyhance™ Toric IOL with the intended axis of placement.
28. The use of methods other than the TECNIS™ Toric Calculator to select cylinder power and appropriate axis of implantation were not assessed in the clinical study for the TECNIS™ Toric 1-Piece IOLs, and may not yield similar results. Accurate keratometry and biometry, in addition to the use of the TECNIS™ Toric Calculator (www.TecnisCalc.com) are recommended to achieve optimal visual outcomes.
29. The safety and effectiveness of the TECNIS Eyhance™ Toric II IOLs have not been substantiated in patients with the following preexisting ocular conditions and intraoperative complications (see below). Careful preoperative evaluation and sound clinical judgment should be used by the surgeon to decide the benefit/risk ratio before implanting a lens in a patient with one or more of these conditions.

**Before Surgery** • Choroidal hemorrhage • Chronic

- severe uveitis • Concomitant severe eye disease • Extremely shallow anterior chamber • Medically uncontrolled glaucoma • Microphthalmos • Non-age-related cataract • Proliferative diabetic retinopathy (Severe) • Severe corneal dystrophy • Severe optic nerve atrophy • Irregular corneal astigmatism
- During Surgery** • Excessive vitreous loss • Capsulotomy by any technique other than a circular tear • The presence of radial tears known or suspected at the time of surgery • Situations in which the integrity of the circular tear cannot be confirmed by direct visualization • Cataract extraction by techniques other than phacemulsification or liquefaction • Situations where the need for a large capsulotomy can be anticipated (e.g., diabetics, retinal detachment in the fellow eye, peripheral retinal pathology, etc.) • Capsular rupture • Significant anterior chamber hyphema • Uncontrollable positive intraocular pressure • Zonular damage
- The PCA is based on an algorithm that combines published literature (Koch et al, 2012) and a retrospective analysis of data from a TECNIS™ Toric multi-center clinical study. The PCA algorithm for the selection of appropriate cylinder power and axis of implantation was not assessed in a prospective clinical study and may yield results different from those in the TECNIS™ Toric intraocular lens labeling. Please refer to the Johnson & Johnson Surgical Vision, Inc. Toric Calculator user manual for more information.
31. All preoperative surgical parameters are important when choosing a toric lens for implantation, including preoperative keratometric cylinder (magnitude and axis), incision location, surgeon's estimated surgically induced astigmatism (SIA) and biometry. Variability in any of the preoperative measurements can influence patient outcomes, and the effectiveness of treating eyes with lower amounts of preoperative corneal astigmatism.
  32. All corneal incisions were placed temporally in the clinical study for the TECNIS™ Toric 1-Piece IOLs. If the surgeon chooses to place the incision at a dif-

ferent location, outcomes may be different from those obtained in the clinical study. Note that the TECNIS™ Toric Calculator incorporates the surgeon's estimated SIA and incision location when providing IOL options.

**ADVERSE EVENTS** Potential adverse events during or following cataract surgery with implantation of an IOL may include but are not limited to: endophthalmitis/intraocular infection, hypopyon, hyphema, IOL dislocation, cystoid macular edema, pupillary block, retinal detachment/tear, persistent corneal stromal edema, persistent iris, persistent raised IOP (intraocular pressure) requiring treatment, acute corneal decompensation, secondary surgical intervention (including implant repositioning, removal, or other surgical procedure) and any other adverse event that leads to permanent visual impairment or requires surgical or medical intervention to prevent permanent visual impairment. The most frequently reported cumulative adverse event that occurred during the SENSAR™ 1-Piece IOL clinical trial was cystoid macular edema which occurred at a rate of 3.3%. Other reported events included secondary surgical intervention (pars plana vitrectomy with membrane peel) which occurred at a rate of 0.8% and lens exchange (tonic haptic related to improper loading technique) which occurred at a rate of 0.8%. The most frequently reported cumulative adverse event that occurred during the TECNIS™ Toric 1-Piece IOL clinical trial was surgical re-intervention which occurred at a rate of 3.4% (lens repositioning procedures and retinal repair procedures). Other reported events included cystoid macular edema which occurred at a rate of 2.9% and retinal detachment which occurred at a rate of 0.6%.

**ATTENTION:** Reference the Directions for Use for a complete listing of Indications and Important Safety Information.